Due to the earlier data about anticancer activity of the cluster rhenium(III) compounds and their synergism with cisplatin, the comparison investigations of influence of this compounds with cisplatin on the human leukemic cells is of great interest. The aim of the work was to compare the cytotoxic activity of the cluster rhenium compound Re2Cl2(C3H7CO2)4(I) in the solutions and nanoliposomes alone and together with cisplatin in Jurkat cells. Cytotoxicity of the substances were investigated against T-cells of acute lymphoblastic leukemia (Jurkat cells) by conventional methods. We have shown that the cytotoxic activity of I and cisplatin was close and the cytotoxic activity of the rhenium-platinum system was much more effective than that of I and cisplatin. In the range of low concentrations I is more effective in solutions than cisplatin that may be the explanation of much lower toxicity of the rhenium compounds and their efficacy in experiments in vivo. Liposomal formulations of investigated preparations are more effective than their solutions, due to a simplified transport mechanism and prevention of the deactivation before penetration to the cancer cell. Liposomal I and antitumor system on its base have LC50 in the range of10-8 M, that is comparable with the LC50 values for the known antitumor drugs and underlines the importance of further investigations of the rhenium cluster compounds as anticancer species. The obtained results underline perspectives of the use of dirhenium compounds in medicines and emphasize the need of further investigations of mechanisms of anticancer activity of the cluster dirhenium(III) compounds. Keywords: cluster rhenium compound; rhenium-platinum antitumor system; cytotoxic activity; apoptosis.